| Quality assessment | Number of patients | Effect | Quality | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Labetalol | Nifedipine | Relative (95% CI) | Absolute | ||
| Stillbirth | ||||||||||||
| 1 (Webster 2017) | randomised trials | serious1 | no serious inconsistency | no serious indirectness | very serious2 | none |
2/55 (3.6%) |
1/57 (1.8%) | RR 2.07 (0.19 to 22.21) | 19 more per 1000 (from 14 fewer to 372 more) | VERY LOW | CRITICAL |
| Neonatal death | ||||||||||||
| 1 (Webster 2017) | randomised trials | serious1 | no serious inconsistency | no serious indirectness | no serious imprecision | none |
0/55 (0%) |
0/57 (0%) | not calculable | not calculable | MODERATE | CRITICAL |
| Small-for-gestational age | ||||||||||||
| 1 (Webster 2017) | randomised trials | serious1 | no serious inconsistency | no serious indirectness | very serious2 | none |
16/55 (29.1%) |
17/57 (29.8%) | RR 0.98 (0.55 to 1.73) | 6 fewer per 1000 (from 134 fewer to 218 more) | VERY LOW | CRITICAL |
| Birth weight (grams) (Better indicated by higher values) | ||||||||||||
| 1 (Webster 2017) | randomised trials | serious1 | no serious inconsistency | no serious indirectness | serious3 | none | 55 | 57 | - | MD 225 higher (85.06 lower to 535.06 higher) | LOW | IMPORTANT |
| Preterm birth (<37 weeks) | ||||||||||||
| 1 (Webster 2017) | randomised trials | serious1 | no serious inconsistency | no serious indirectness | serious4 | none |
12/55 (21.8%) |
20/57 (35.1%) | RR 0.62 (0.34 to 1.15) | 133 fewer per 1000 (from 232 fewer to 53 more) | LOW | IMPORTANT |
| Preterm birth (<34 weeks) | ||||||||||||
| 1 (Webster 2017) | randomised trials | serious1 | no serious inconsistency | no serious indirectness | very serious2 | none |
10/55 (18.2%) |
11/57 (19.3%) | RR 0.94 (0.44 to 2.04) | 12 fewer per 1000 (from 108 fewer to 201 more) | VERY LOW | IMPORTANT |
| Admission to neonatal unit | ||||||||||||
| 1 (Webster 2017) | randomised trials | serious1 | no serious inconsistency | no serious indirectness | very serious2 | none |
11/55 (20%) |
15/57 (26.3%) | RR 0.76 (0.38 to 1.51) | 63 fewer per 1000 (from 163 fewer to 134 more) | VERY LOW | IMPORTANT |
| Gestational age at birth, weeks (Better indicated by higher values) | ||||||||||||
| 1 (Webster 2017) | randomised trials | serious1 | no serious inconsistency | no serious indirectness | no serious imprecision | none | 55 | 57 | - | MD 0.63 higher (0.41 to 0.85 higher) | MODERATE | IMPORTANT |
| Mode of birth (caesarean section) | ||||||||||||
| 1 (Webster 2017) | randomised trials | serious1 | no serious inconsistency | no serious indirectness | very serious2 | none |
17/55 (30.9%) |
21/57 (36.8%) | RR 0.84 (0.50 to 1.41) | 59 fewer per 1000 (from 184 fewer to 151 more) | VERY LOW | IMPORTANT |
| Superimposed pre-eclampsia | ||||||||||||
| 1 (Webster 2017) | randomised trials | serious1 | no serious inconsistency | no serious indirectness | serious4 | none |
8/55 (14.5%) |
15/57 (26.3%) | RR 0.55 (0.25 to 1.20) | 118 fewer per 1000 (from 197 fewer to 53 more) | LOW | IMPORTANT |
| Superimposed pre-eclampsia < 34 weeks | ||||||||||||
| 1 (Webster 2017) | randomised trials | serious1 | no serious inconsistency | no serious indirectness | very serious2 | none |
6/55 (10.9%) |
6/57 (10.5%) | RR 1.04 (0.36 to 3.02) | 4 more per 1000 (from 67 fewer to 213 more) | VERY LOW | IMPORTANT |
| Eclampsia | ||||||||||||
| 1 (Webster 2017) | randomised trials | serious1 | no serious inconsistency | no serious indirectness | no serious imprecision | none |
0/55 (0%) |
0/57 (0%) | not calculable | not calculable | MODERATE | IMPORTANT |
| Maternal death | ||||||||||||
| 1 (Webster 2017) | randomised trials | serious1 | no serious inconsistency | no serious indirectness | no serious imprecision | none |
0/55 (0%) |
0/57 (0%) | not calculable | not calculable | MODERATE | IMPORTANT |
The quality of the evidence was downgraded by 1 level due to unclear risk of allocation concealment and a high risk of performance and detection bias
The quality of the evidence was downgraded by 2 levels as the 95% CI crossed 2 default MID thresholds (0.8 and 1.25)
The quality of the evidence was downgraded by 1 level as the 95% CI crossed 1 default MID threshold (883 × +/− 0.5= +/− 441.5)
95% CI crossed 1 default MID threshold (0.8)
From: Evidence review for interventions for chronic hypertension
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.